Glucocorticoids ameliorate antigen-induced bronchial smooth muscle hyperresponsiveness by inhibiting upregulation of RhoA in rats

Journal of Pharmacological Sciences

Volumn 106, Issue 4, 2008, Pages 615-625

  Chiba, Yoshihiko ^a   Goto, Kumiko ^a   Hirahara, Mayu ^a   Sakai, Hiroyasu ^a   Misawa, Miwa ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Airway hyperresponsiveness; Beclomethasone; Bronchial smooth muscle; Prednisolone; RhoA

Indexed keywords

2,4 DINITROPHENOL; ACETYLCHOLINE; ASCARIS ANTIGEN; BECLOMETASONE; GLUCOCORTICOID; MYOSIN LIGHT CHAIN; PREDNISOLONE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; BRONCHUS MUSCLE; CONTROLLED STUDY; DRUG MECHANISM; MALE; MUSCLE CONTRACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; SMOOTH MUSCLE CONTRACTILITY; STEROID THERAPY;

EID: 42349098821     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071825     Document Type: Article

References (60)

1. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. Am Rev Respir Dis. 1980;121:389-413.
2. Jeffery PK. Microscopic structure of airway secretory cells: variation in hypersecretory disease and effects of drugs. In: Takishima T, Shimura S, editors. Airway secretion: physiological basis for the control of mucus hypersecretion. New York, NY: Marcel Dekker; 1993. p. 149-215.
3. Wiggs BR, Moreno R, Hogg JC, Hilliam C, Pare PD. A model of the mechanics of airway narrowing. J Appl Physiol. 1990;69:849-860.
4. Seow CY, Schellenberg RR, Pare PD. Structural and functional changes in the airway smooth muscle of asthmatic subjects. Am J Respir Crit Care Med. 1998;158:S179-S186.
5. Martin JG, Duguet A, Eidelman DH. The contribution of airway smooth muscle to airway narrowing and airway hyperresponsiveness in disease. Eur Respir J. 2000;16:349-354.
6. 2+ sensitization. Am J Respir Cell Mol Biol. 1999;20:1190-1200.
7. 2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Br J Pharmacol. 1999;127:597-600.
8. Kai T, Yoshimura H, Jones KA, Warner DO. Relationship between force and regulatory myosin light chain phosphorylation in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2000;279:L52-L58.
9. 2+ sensitization and mobilization by MCh in tracheal smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2001;280:L1218-L1224.
10. 2+ sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice. Respir Res. 2005;6:Art. No. 4.
11. Sakai H, Chiba Y, Hirano T, Misawa M. Possible involvement of CPI-17 in augmented bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Mol Pharmacol. 2005;68:145-151.
12. Chiba Y, Murata M, Ushikubo H, Yoshikawa Y, Saitoh A, Sakai H, et al. Effect of cigarette smoke exposure in vivo on bronchial smooth muscle contractility in vitro in rats. Am J Respir Cell Mol Biol. 2005;33:574-581.
13. 2+-sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. J Clin Invest. 1994;94:1397-1403.
14. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029-1039.
15. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 2000;101:1319-1323.
16. Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rhokinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000;87:195-200.
17. Chrissobolis S, Sobey CG. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension: comparison with protein kinase C. Circ Res. 2001;88:774-779.
18. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93:225-232.
19. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
20. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062-1064.
21. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res. 2003;92:411-418.
22. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med. 1996;154:S21-S27.
23. Hirst SJ, Lee TH. Airway smooth muscle as a target of glucocorticoid action in the treatment of asthma. Am J Respir Crit Care Med. 1998;158:201S-206S.
24. Panettieri RA Jr. Effects of corticosteroids on structural cells in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:231-234.
25. Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med. 1996;154:771-782.
26. Sotomayor H, Badier M, Vervloet D, Orehek J. Seasonal increase of carbachol airway responsiveness in patients allergic to grass pollen. Reversal by corticosteroids. Am Rev Respir Dis. 1984;130:56-58.
27. Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 2002;166:1212-1217.
28. Currie GP, Stenback S, Lipworth BJ. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol. 2003;56:11-17.
29. Nomura S, Kanazawa H, Asai K, Nomura N, Hirata K, Yoshikawa J. Potential mechanisms of improvement of airway hyperresponsiveness by inhaled corticosteroid therapy in asthmatic patients. J Asthma. 2006;43:113-117.
30. Chiba Y, Sakai H, Yu Y, Misawa M. Effects of repeated antigen exposure on endothelin-1-induced bronchial smooth muscle contraction and activation of RhoA in sensitized rats. J Biochem. 2005;137:751-756.
31. 2+ availability involved in antigen-induced airway hyperresponsiveness in rats. Eur J Pharmacol. 1995;278:79-82.
32. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720-1745.
33. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533:2-14.
34. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998;157:S1-S53.
35. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol. 2001;107:937-944.
36. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977;7:235-243.
37. Hargreave FE, Ryan G, Thomson NC, O'Byrne PM, Latimer K, Juniper EF, et al. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol. 1981;68:347-355.
38. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033-1039.
39. Kraneveld AD, Folkerts G, Van Oosterhout AJ, Nijkamp FP. Airway hyperresponsiveness: first eosinophils and then neuropeptides. Int J Immunopharmacol. 1997;19:517-527.
40. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255-281.
41. Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE, et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med. 1997;185:2143-2156.
42. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144-2148.
43. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167:1655-1659.
44. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med. 1997; 155:1529-1534.
45. Gauvreau GM, Wood LJ, Sehmi R, Watson RM, Dorman SC, Schleimer RP, et al. The effects of inhaled budesonide on circulating eosinophil progenitors and their expression of cytokines after allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med. 2000;162:2139-2144.
46. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med. 1996;183:109-117.
47. Eum SY, Maghni K, Hamid Q, Eidelman DH, Campbell H, Isogai S, et al. Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: role of eosinophils, IL-5, eotaxin, and IL-13. J Allergy Clin Immunol. 2003;111:1049-1061.
48. Misawa M, Chiba Y. Repeated antigenic challenge-induced airway hyperresponsiveness and airway inflammation in actively sensitized rats. Jpn J Pharmacol. 1993;61:41-50.
49. Chiba Y, Misawa M. Strain differences in change in airway responsiveness after repeated antigenic challenge in three strains of rats. Gen Pharmacol. 1993;24:1265-1272.
50. Gosens R, Schaafsma D, Nelemans SA, Halayko AJ. Rho-kinase as a drug target for the treatment of airway hyperresponsiveness in asthma. Mini Rev Med Chem. 2006;6:339-348.
51. Takizawa T, Kawada N, Tanaka H, Nagai H. Effect of antiallergic drugs on interleukin 5-induced eosinophil infiltration of rat airways. Biol Pharm Bull. 2002;25:318-322.
52. Amrani Y, Panettieri RA Jr. Cytokines induce airway smooth muscle cell hyperresponsiveness to contractile agonists. Thorax. 1998;53:713-716.
53. Sakai H, Otogoto S, Chiba Y, Abe K, Misawa M. TNF-alpha augments the expression of RhoA in the rat bronchus. J Smooth Muscle Res. 2004;40:25-34.
54. Sakai H, Otogoto S, Chiba Y, Abe K, Misawa M. Involvement of p42/44 MAPK and RhoA protein in augmentation of AChinduced bronchial smooth muscle contraction by TNF-alpha in rats. J Appl Physiol. 2004;97:2154-2159.
55. Ammit AJ, Hoffman RK, Amrani Y, Lazaar AL, Hay DW, Torphy TJ, et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smoothmuscle cells. Modulation by cyclic adenosine monophosphate. Am J Respir Cell Mol Biol. 2000;23:794-802.
56. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF. Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med. 1998;158:1585-1592.
57. Desmet C, Gosset P, Henry E, Garze V, Faisca P, Vos N, et al. Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. Am J Respir Crit Care Med. 2005;172:671-678.
58. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994;91:752-756.
59. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990;62:1217-1226.
60. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27:413-426.